Shanghai, September 8, 2021-Insi Intelligence (Insilico Medicine) and East China Medicine (SZ.000963) today announced a partnership to accelerate the research and development of innovative small molecular drugs in the field of oncology.
According to the agreement, Yingsi Intelligence and East China Pharmaceutical will launch a new drug discovery project with the cooperation of the scientific research teams of both sides. By interfering with protein-protein interactions, the project team will target "non-drug" targets that regulate tumor growth, and make use of Insi intelligent end-to-end artificial intelligence drug development platform, especially small molecule generation platform Chemistry42, combined with East China Pharmaceutical's advanced innovative drug discovery and screening characterization platform. Potential first-in-class (FIC) drug molecules with novelty, high activity and high potency were designed and screened.
Yingsi Intelligence is an end-to-end innovative drug research and development company driven by artificial intelligence. its self-developed small molecular compound design and generation platform Chemistry42 combines artificial intelligence technology with computing and pharmaceutical chemical methods to efficiently generate new molecular structures with predefined characteristics for specific targets, helping to screen and obtain drug molecules that can be verified in vitro and in vivo. Rapid realization from the discovery of budding compounds to the identification of clinical compounds.
East China Pharmaceutical is a listed pharmaceutical company integrating R & D, manufacturing, sales and commerce, with more than 10, 000 employees in China, sales channels covering more than 10, 000 large and medium-sized hospitals, and more than 1000 R & D personnel, covering all aspects of drug discovery, preclinical research, clinical research, CMC and registration. East China Pharmaceutical focuses on innovation and transformation strategy, focusing on advantages and R & D resources, and building forward-looking anti-tumor, endocrine / metabolic and autoimmune disease innovative product R & D pipelines with the help of advanced technologies of partners.
Dr. Ren Feng, chief scientific officer of Yingsi Intelligence and head of drug research and development, said, "complementary advantages and cooperative innovation have increasingly become the trend of new drug research and development." We are honored to cooperate with East China Pharmaceutical to give full play to the advantages of Yingsi's intelligent and advanced generation chemistry platform Chemistry42 and East China Pharmaceutical's powerful target verification and screening platform to jointly challenge the traditional 'non-proprietary medicine' targets such as protein-protein interaction to solve unmet clinical needs more efficiently. "
Dr. Liu Dongzhou, Chief Scientific Officer of East China Pharmaceutical and General Manager of the Innovation Drug Research and Development Center, said, "the introduction of artificial intelligence into new drug research and development can greatly improve the efficiency of drug research and development. It can effectively accelerate the time from drug design, discovery, preclinical research and development to clinical development and reduce the cost of research and development. We look forward to working with Insi Intelligence, a leading international AI company, to develop potential FIC drug molecules to meet rising clinical medical needs, while providing more optimal and even subversive treatment options for patients. "